Glaukos Corporation director Mark J. Foley reported an equity award in the form of restricted stock units. On 01/02/2026, he received 1,168 restricted stock units of Glaukos common stock at a stated price of $0 per share under the company’s Director Compensation Policy. These units will vest in full on the one-year anniversary of the grant date and are then payable in an equivalent number of Glaukos common shares.
Following this grant, Foley beneficially owns 58,389 shares of common stock, which the disclosure notes includes 3,276 restricted stock units that have not yet vested or been delivered.
Glaukos Corporation granted director Marc Stapley 727 restricted stock units on 01/02/2026. These units were issued under the company’s Director Compensation Policy, will vest in full one year after the grant date, and will be settled in the same number of Glaukos common shares.
Following this award, Stapley beneficially owns 37,449 shares of Glaukos common stock, which includes 2,835 restricted stock units that have not yet vested or been delivered, as well as vested units whose delivery has been deferred.
Glaukos Corporation's Chief Development Officer reported a routine share withholding related to equity compensation. On 12/30/2025, 510 shares of common stock were withheld by the company at $114.24 per share to cover tax obligations when previously granted restricted stock units vested. After this transaction, the officer beneficially owned 77,451 shares of common stock. This total includes 43,562 restricted stock units that have been granted but have not yet vested or been delivered, meaning they may convert into shares over time if service or other conditions are met.
Glaukos Corporation’s Chairman, CEO and director reported an insider stock transaction dated 12/30/2025. The filing shows that 1,098 shares of common stock were withheld by the company to satisfy the reporting person’s tax withholding obligations when restricted stock units granted on March 24, 2022 vested and were delivered.
After this tax-withholding transaction, the insider beneficially owned 153,775 shares of Glaukos common stock. This total includes 89,621 restricted stock units that have been granted but have not yet vested or been delivered.
Glaukos Corporation’s chairman and CEO reported earning 4,168 shares of common stock tied to a performance-based restricted stock unit award granted on March 24, 2022. The board’s Compensation, Nominating and Governance Committee determined certain operational targets were achieved, so this portion of the award was earned at a reported price of $0 per share.
Half of these 4,168 shares are scheduled to vest and be delivered in March 2026 and the other half in December 2026. Following this transaction, 154,873 shares are beneficially owned directly, including 91,705 restricted stock units that have not yet vested or been delivered, and additional indirect holdings are reported through several Burns family and charitable trusts. The CEO also acquired 8,416 stock options at an exercise price of $55.18 per share from the same 2022 performance award, which will vest 50% in March 2026 and 50% in December 2026 and are part of 86,262 stock options held directly, expiring on March 24, 2032.
Glaukos Corp reported that its President and COO acquired 7,316 stock options on 12/11/2025 under a previously granted award tied to pre-determined operational targets. These options have an exercise price of $55.18 and were earned after the Compensation, Nominating & Governance Committee determined that certain operational targets over a multi-year performance period had been achieved.
The options represent a portion of an award originally granted on March 24, 2022, and will vest in two equal installments, with 50% becoming exercisable in March 2026 and the remaining 50% in December 2026. Following this transaction, the executive beneficially owned 65,013 derivative securities, held directly.
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.
Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.
Glaukos Corporation’s Chief Development Officer reported an equity award update. On December 11, 2025, the officer was credited with 2,054 shares of common stock at a price of $0, tied to a previously granted restricted stock unit (RSU) award from March 24, 2022 that depended on meeting pre-set operational targets over a multi-year period.
The board’s Compensation, Nominating and Governance Committee determined that certain of these targets had been achieved, and this share amount represents the portion of the award earned based on that performance. Half of these shares will vest and be delivered in March 2026, with the remaining half vesting and delivering in December 2026. After this update, the officer beneficially owns 77,961 shares, including 44,589 RSUs that are still unvested.
Glaukos Corp (GKOS) director transaction: On 12/09/2025, a director exercised a stock option to acquire 5,000 shares of common stock at an exercise price of $24.69 per share, then sold 5,000 shares of common stock on the same date at a weighted average price of $107.27 per share across multiple trades.
After these transactions, the director beneficially owns 34,905 shares of Glaukos common stock, which includes 2,569 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The director also continues to hold 10,000 stock options with an exercise price of $24.69, originally granted in 2016 and already fully vested.
Glaukos Corporation insider has filed notice of a planned sale of common stock under Rule 144. The seller plans to sell 5,000 shares of Glaukos common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $536,368.18. The filing notes that 57,434,740 shares of Glaukos common stock were outstanding at the time referenced. The shares to be sold were acquired on 12/09/2025 through an option granted on 06/02/2016, with cash as the form of payment. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Glaukos’ current or prospective operations.